ARBUTUS BIOPHARMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.73 USD | +0.37% |
|
+0.37% | +9.20% |
| Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
| Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 224.2 | 383.6 | 664.8 | 494 | 555.3 | 673.3 | - | - |
| Enterprise Value (EV) 1 | 224.2 | 383.6 | 664.8 | 494 | 555.3 | 673.3 | 673.3 | 673.3 |
| P/E ratio | -0.93 x | -3.58 x | -4.68 x | -5.04 x | -5.54 x | -6.18 x | -5.2 x | -3.24 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 27.8 x | 44 x | 47.8 x | 9.3 x | 22.5 x | 53.3 x | 49.5 x | 41.2 x |
| EV / Revenue | 27.8 x | 44 x | 47.8 x | 9.3 x | 22.5 x | 53.3 x | 49.5 x | 41.2 x |
| EV / EBITDA | -2,407,062 x | - | - | - | - | - | - | - |
| EV / FCF | -2,336,661 x | -5,893,587 x | - | - | - | - | - | - |
| FCF Yield | -0% | -0% | - | - | - | - | - | - |
| Price to Book | - | 2.67 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 62,112 | 84,909 | 135,269 | 156,467 | 167,695 | 180,175 | - | - |
| Reference price 2 | 3.610 | 4.518 | 4.915 | 3.157 | 3.312 | 3.737 | 3.737 | 3.737 |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/2/23 | 2/29/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.061 | 8.718 | 13.92 | 53.12 | 24.63 | 12.63 | 13.59 | 16.33 |
| EBITDA | -93.16 | - | - | - | - | - | - | - |
| EBIT 1 | -193.2 | -72.89 | -93.12 | -89.11 | -106 | -120.8 | -137.9 | -228.1 |
| Operating Margin | -2,396.84% | -836.07% | -669.11% | -167.75% | -430.53% | -956.87% | -1,014.56% | -1,396.94% |
| Earnings before Tax (EBT) 1 | -223.1 | -80.38 | -96.57 | -88.51 | -98.9 | -113.1 | -129.9 | -219.3 |
| Net income 1 | -221.1 | -95.66 | -111.9 | -94.56 | -98.9 | -113.1 | -129.9 | -219.3 |
| Net margin | -2,742.84% | -1,097.31% | -804.39% | -178.01% | -401.57% | -895.37% | -955.69% | -1,342.93% |
| EPS 2 | -3.875 | -1.261 | -1.051 | -0.6263 | -0.5974 | -0.6046 | -0.7193 | -1.154 |
| Free Cash Flow | -95.97 | -65.09 | - | - | - | - | - | - |
| FCF margin | -1,190.59% | -746.64% | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/2/23 | 2/29/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.146 | 4.06 | 16.15 | 18.31 | 8.009 | 8.502 | 9.107 | 6.202 | 6.37 | 2.912 | 3.682 | 3.604 | 3.526 | 3.349 | 2.881 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -22.85 | -26.34 | -14.09 | -18.14 | -23.97 | -30.72 | -23.72 | -24.51 | -29.48 | -28.17 | -27.74 | -29.08 | -30.86 | -33.16 | -35.94 |
| Operating Margin | -551.14% | -648.66% | -87.23% | -99.07% | -299.24% | -361.28% | -260.4% | -395.29% | -462.82% | -967.23% | -753.42% | -806.84% | -875.02% | -990.24% | -1,247.58% |
| Earnings before Tax (EBT) 1 | -23.78 | -27 | -14.53 | -18.24 | -23.64 | -29.86 | -22.25 | -22.79 | -27.49 | -26.22 | -25.81 | -27.14 | -28.91 | -31.21 | -34.01 |
| Net income 1 | -30.1 | -27.73 | -20.24 | -18.24 | -23.64 | -29.86 | -22.25 | -22.79 | -27.49 | -26.22 | -25.81 | -27.14 | -28.91 | -31.21 | -34.01 |
| Net margin | -725.9% | -682.94% | -125.31% | -99.66% | -295.14% | -351.19% | -244.34% | -367.53% | -431.6% | -900.33% | -700.96% | -753.06% | -819.87% | -931.97% | -1,180.78% |
| EPS 2 | -0.2979 | -0.1900 | -0.1412 | -0.1286 | -0.1615 | -0.1906 | -0.1362 | -0.1333 | -0.1641 | -0.1629 | -0.1492 | -0.1460 | -0.1595 | -0.1662 | -0.1965 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/3/22 | 5/5/22 | 8/4/22 | 11/9/22 | 3/2/23 | 5/4/23 | 8/3/23 | 11/7/23 | 2/29/24 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -96 | -65.1 | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | 1.690 | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.79 | 0.29 | 1.03 | - | - | - | - | - |
| Capex / Sales | 9.79% | 3.31% | 7.37% | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/2/23 | 2/29/24 | - | - | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.737
CAD
Average target price
5.962
CAD
Spread / Average Target
+59.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.20% | 492M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- ABUS Stock
- Financials Arbutus Biopharma Corporation
